Advanced Medical Optics Reiterates Guidance for 2002 and 2003.

Business Editors & Health/Medical Writers

SANTA ANA, Calif.--(BUSINESS WIRE)--Nov. 6, 2002

Advanced Medical Optics, Inc. (NYSE:AVO), a global leader in ophthalmic surgical devices and contact lens care products, today expressed confidence in guidance it has provided for the fourth quarter and full year 2002 and provided its initial guidance for 2003.

The Company estimates it will generate revenue of $530-535 million, deliver proforma earnings per share of $0.56-0.57 and achieve proforma EBITDA of $69-72 million for the full year 2002. As a result, the Company expects fourth quarter 2002 revenues will be $140-145 million, earnings per share of $0.28-0.29 and EBITDA of $25-27 million. Going forward, the Company expects revenues to grow in the mid-single digit range, and earnings per share growth in the mid-teens. Therefore, the Company's guidance for the full year 2003 is revenue of $545-555 million and earnings per share of $0.65-0.67.

About Advanced Medical Optics

Advanced Medical Optics, Inc. (AMO) is a global leader in the development, manufacturing and marketing of medical devices for the eye and contact lens care products. The Company focuses on developing a broad suite of innovative technologies and devices to address a wide range of eye disorders. Products in the ophthalmic surgical line include foldable intraocular lenses, phacoemulsification systems, viscoelastics and related products used in cataract surgery and microkeratomes used in LASIK procedures for refractive error correction. Among the well-known ophthalmic surgical product brands the company owns or has the rights to are Phacoflex(R), Clariflex(R), Array(R) and Sensar(R) foldable intraocular lenses, the Sovereign(R) phacoemulsification system and the Amadeus(TM) microkeratome. Products in the contact lens care line include disinfecting solutions, daily cleaners, enzymatic cleaners and lens rewetting drops. Among the well-known contact lens care product brands the company possesses are Complete(R), Complete(R) Blink-N-Clean(R), Consept(R)F, Consept(R) 1 Step, Oxysept(R) 1 Step, Ultracare(R), Ultrazyme(R) and Total Care(R). Amadeus is a licensed product of, and a trademark of, SIS, Ltd. OptiEdge is a trademark of Ocular Sciences, Inc.

Advanced Medical Optics, Inc. is based in Orange County, California, and employs approximately 2,000 worldwide. The company has operations in about 20 countries and markets products in approximately 60 countries. For more information, visit the company's web site at www.amo-inc.com.

Forward-Looking Statements

This press release contains forward-looking statements and forecasts about AMO and its businesses. Because forecasts are inherently estimates that cannot be made with precision, the Company's performance at times differs from its estimates and targets, and the Company often does not know what the actual results will be until after a quarter's end. Therefore, the Company will not report or comment on its progress during the quarter. Any statement made by others with respect to progress mid-quarter cannot be attributed to the Company.

Any statements in this press release that refer to AMO's estimated or anticipated future results are forward-looking statements. All forward-looking statements in this press release reflect AMO's current analysis of existing trends and information and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors affecting AMO's businesses, including but not limited to competitive, regulatory and market conditions; the performance acceptance of new products and the continuing acceptance of current products; the execution of strategic initiatives; AMO's ability to maintain a sufficient supply of products; and the uncertainties associated with intellectual property protection for these products. In addition, matters generally affecting the domestic and global economy, such as changes in interest and currency exchange rates, can affect AMO's results. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors can be found in press releases issued by AMO as well as AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in the Information Statement filed as an exhibit to the amended Form 10 filed by AMO with the Securities and Exchange Commission on May 24, 2002. Copies of press releases and additional information about AMO are available on the World Wide Web at www.amo-inc.com, or you can contact the AMO Investor Relations Department by calling 714/247-8348.